COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...
19h
Bio Behavioral Health Joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials
PhaseWell Research ("PhaseWell"), a national clinical research site company, today announced a new partnership with Bio ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...
Primrose Bio’s advanced technology for manufacturing nucleic acids and proteins makes it the partner of choice for pharma companies developing new vaccines, therapeutics and bio-based products.
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback